 Daily News & Analysis | How breast cancer cells acquire drug resistance Daily News & Analysis Gefitinib is a targeted cancer therapy that blocks a tyrosine kinase enzyme to treat non-small cell lung cancers caused by mutations in the epidermal growth factor receptor. “This study raises the possibility that resistance to other tyrosine kinase ... |
